MB BCh BAO, MD, MFMHM FRCP (Ed) is an internationally respected clinical epidemiologist whose research focuses on diabetes and its complications. She holds a prestigious AXA Research Fund personal endowed Chair in Medical Informatics and Epidemiology and is well established as a trialist having led the international guideline changing CARDS trial of atorvastatin in diabetes. She sits on the Steering Committee of various important international trials in diabetes, on which she has provided design and analysis input, including the ongoing REWIND trial (Eli Lilly – dulaglutide CVD endpoint trial), REMOVAL trial (JDRF – metformin in type 1 diabetes recently completed), and the ODYSSEY Phase 3 a programme of Alirocumab funded by Sanofi/ Regeneron. She has extensive experience in complex data analysis in diabetes and co-led the IMI funded SUMMIT programme. She sits on many advisory boards and grant giving bodies and is currently a Chair of the Wellcome Trust Science Interview panel, a member of the Diabetes UK research Committee and the Wellcome Trust Science Strategy panel. She recently led the MRC-funded Farr Scotland pharmacoepidemiology research programme and national databasing programme for drugs. She has recently sat on a Scottish Government Short Life Working group on medical Informatics for national drugs policy. She will oversee all activities being led by Edinburgh e.g. refining the design and analysis plans, overseeing data analysis, reviewing and checking analysis output, lead regular teleconferences with all key persons to discuss the results.
